Overactive Bladder Market Report and Forecast 2024-2032

Overactive Bladder Market Outlook

The overactive bladder market size is expected to grow at a CAGR of 2.52% during the forecast period of 2024-2032, driven by the rising prevalence and incidence of overactive bladder disorders and the introduction of novel treatment therapies across 8 major markets.

Overactive Bladder Market Overview

Overactive bladder (OAB) is a medical condition that causes the frequent and sudden urge to urinate. It can result in unintentional loss of urine (urgency incontinence). Overactive bladder syndrome shows a high prevalence rate of 17% in adults. In children, the incidence of overactive bladder is nearly 16.6%.  However, similar incidence rates are witnessed in men and women. The rising cases of the condition is anticipated to augment the overactive bladder market growth in the forecast period.

The surge in drugs and medical device approvals by health regulatory agencies is likely to impact the market dynamics positively. In August 2023, the United States Food and Drug Administration (FDA)  granted marketing approval to an implant called Revi System. The minimally invasive device, developed by Utah-based medical equipment supplier BlueWind Medical is aimed at treating overactive bladder. It works on neuromodulation therapy to manage symptoms of overactive bladder. The introduction of such novel treatment options in the market is likely to increase the overactive bladder market demand.

Several leading biopharmaceutical companies are actively investing in research and development activities to support the launch of potential treatment therapies for patients suffering from overactive bladder. Such strategic investments are anticipated to bolster the overactive bladder market growth. Moreover, the evolving preference for minimally invasive procedures such as neurostimulation will boost the market growth.

Overactive Bladder Market Trends

Overactive Bladder Market Segmentation

Market Breakup by Drug Type

• Anti Cholinergic Drug

• Beta 3 Adrenergic Drugs

• Botox

• Neurostimulation

• Intravesical Instillation

The market segmentation by drug type includes anti-cholinergic drugs, beta-3 adrenergic drugs, botox, neurostimulation, and intravesical instillation. Catering to the diverse needs of the patients, this segmentation offers a variety of pharmacological and non-pharmacological options to treat and manage overactive bladder.

Market Breakup by Disease Type

• Idiopathic Bladder Overactivity

• Neurogenic Bladder Overactivity

The overactive bladder market share is segmented by disease type into idiopathic bladder overactivity and neurogenic bladder overactivity. Idiopathic bladder overactivity is characterized by overactive bladder symptoms without a known underlying cause whereas neurogenic bladder overactivity occurs as a result of underlying neurological conditions.

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

• Others

The distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and others. To ensure accessibility and availability of overactive bladder treatments, this segment offers various channels to cater to the growing patient base.

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • o    Italy
  • o    Spain
  • o    United Kingdom
• Japan

• India

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. North America dominates the regional market, with factors such as the presence of key market players along with a robust healthcare system. The rise in the launch of novel therapies in the region further bolsters the market growth.

Overactive Bladder Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• AbbVie Inc.

• Astellas Pharma Inc.

• Pfizer Inc.

• Sumitomo Pharma Co., Ltd

• Laborie

• Endo International PLC

• Hisamitsu Pharmaceutical Co., Inc.

• Medtronic

• Urovant Sciences

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Key Queries Solved in the Overactive Bladder Market Report

• How will the market landscape evolve in the forecast period? 
• What are the leading factors driving the growth of the market?
• What are the strategic investments being made by biopharmaceutical companies to develop novel drugs for overactive bladder treatment?
• Which diseases and conditions majorly contribute to the prevalence of the overactive bladder?
• What is the current incidence of overactive bladder, and how is it expected to impact the overactive bladder market size?
• Which drug type is predicted to dominate the overactive bladder market?
• What are the emerging trends in minimally invasive procedures for overactive bladder management, and how do they influence market dynamics?
• What are the challenges and constraints in the market?
• How do regulatory frameworks and reimbursement policies impact the market landscape?
• What are the key market segments and their respective growth trajectories?
• What are the competitive dynamics among key players in the market?
• What are the opportunities for growth and innovation in the overactive bladder market in the coming years?